Insider Selling: GoodRx (NASDAQ:GDRX) Major Shareholder Sells $496,835.24 in Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX) major shareholder Francisco Partners Iv, L.P. sold 143,594 shares of the business’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $3.46, for a total value of $496,835.24. Following the sale, the insider directly owned 706,649 shares in the company, valued at $2,445,005.54. This trade represents a 16.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

• On Wednesday, August 26th, Francisco Partners Iv, L.P. sold 1,296,177 shares of GoodRx stock. The stock was sold at an average price of $3.50, for a total transaction of $4,536,619.50.
• On Tuesday, August 25th, Francisco Partners Iv, L.P. sold 127,273 shares of GoodRx stock. The stock was sold at an average price of $3.44, for a total transaction of $437,819.12.
• On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The stock was sold at an average price of $3.50, for a total transaction of $961,509.50.
• On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The shares were sold at an average price of $3.52, for a total transaction of $1,574,351.68.
• On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The shares were sold at an average price of $3.53, for a total transaction of $1,666,071.75.

GoodRx Trading Up 5.2%

Shares of NASDAQ:GDRX traded up $0.18 during mid-day trading on Wednesday, hitting $3.65. The stock had a trading volume of 3,534,816 shares, compared to its average volume of 1,909,305. The company’s 50 day moving average is $3.18 and its 200-day moving average is $2.66. GoodRx Holdings, Inc. has a 12-month low of $1.77 and a 12-month high of $5.81. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.38 and a current ratio of 1.38. The company has a market cap of $1.25 billion, a PE ratio of 91.27, a P/E/G ratio of 1.73 and a beta of 1.60.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, hitting the consensus estimate of $0.08. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The firm had revenue of $200.41 million for the quarter, compared to analysts’ expectations of $193.23 million. During the same period in the previous year, the company posted $0.09 EPS. The company’s quarterly revenue was down 1.3% compared to the same quarter last year. On average, sell-side analysts predict that GoodRx Holdings, Inc. will post 0.16 EPS for the current year.

Analyst Ratings Changes

GDRX has been the topic of a number of research analyst reports. Wall Street Zen upgraded GoodRx from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Wells Fargo & Company raised their price objective on GoodRx from $3.50 to $5.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Weiss Ratings raised GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, August 7th. Barclays lifted their target price on GoodRx from $3.00 to $4.00 and gave the company an “underweight” rating in a research note on Thursday, August 20th. Finally, Citigroup increased their price target on shares of GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating, six have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, GoodRx currently has an average rating of “Hold” and a consensus target price of $4.23.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of GDRX. Lazard Asset Management LLC raised its stake in shares of GoodRx by 43.6% during the 2nd quarter. Lazard Asset Management LLC now owns 17,142 shares of the company’s stock worth $85,000 after purchasing an additional 5,201 shares in the last quarter. Brevan Howard Capital Management LP lifted its holdings in shares of GoodRx by 7.7% during the 3rd quarter. Brevan Howard Capital Management LP now owns 95,483 shares of the company’s stock valued at $404,000 after buying an additional 6,842 shares during the last quarter. Hirtle Callaghan & Co LLC grew its stake in shares of GoodRx by 60.3% in the 4th quarter. Hirtle Callaghan & Co LLC now owns 18,261 shares of the company’s stock valued at $49,000 after buying an additional 6,869 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of GoodRx by 202.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock valued at $56,000 after buying an additional 7,580 shares in the last quarter. Finally, Quarry LP acquired a new position in GoodRx in the third quarter worth approximately $33,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.